Growth in sales of Tysabri, Biogen's and Elan's
And yet many patients aren't convinced. There are other treatments for multiple sclerosis available, like Biogen's Avonex, Teva Pharmaceutical's
Elan and Biogen can't make Tysabri any more effective, so the only way to get sales growing again at the previous feverish clip is to decrease the risk of PML. The companies are working on two fronts: trying to figure out how to detect PML so that it can be diagnosed early and how to treat patients once they get it.
Biogen hopes to have a test for the virus that causes PML available by the end of the year although, because the virus is present in many healthy individuals, it's not entirely clear if a test will be very useful. More importantly, the companies are working on a procedure for treating patients who have PML. The first step is a system for removing Tysabri from the blood stream -- Tysabri inhibits the mistaken attack of the body by the immune system that is MS. This inhibition is thought to allow the virus to induce PML. They're also testing a malaria drug sold by Roche to see if it's capable of treating the disease.
Ultimately it'll be how well patients survive PML, not the frequency of PML, that will help skew the risk-reward profile further in favor of Tysabri. So far five patients have gotten PML since Tysabri was brought back on the market, with one death.
With every drug, the side effect profile is going to be judged against its efficacy. In some cases, like Merck's
Some side effects of Foolishness are education, amusement, and enrichment:
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is an Inside Value recommendation. Elan is a Rule Breakers selection. The Fool's disclosure policy is a side effect of our integrity.